Amrn stock globe and mail
You're looking for information on Amarin Corporation (AMRN) stock from The Globe and Mail. Here's a summary of the latest news and analysis:
Latest News:
- Amarin Corporation (AMRN) stock has been on a tear lately, surging over 20% in the past week alone. The company's shares have been boosted by positive news on its cardiovascular disease treatment, Vascepa.
- In a recent article, The Globe and Mail noted that Amarin's stock has been a "top performer" in the biotech sector, with its market capitalization increasing by over 50% in the past year.
- The company's Vascepa treatment has been approved by the US FDA for reducing cardiovascular risk in patients with high triglycerides, and Amarin is working to expand its use to other patient populations.
Analysis:
- According to a recent article in The Globe and Mail, Amarin's stock has been driven by a combination of factors, including the company's strong financial performance and the growing demand for its Vascepa treatment.
- The article noted that Amarin's revenue has been increasing steadily, driven by the growing adoption of Vascepa and the company's expanding presence in the cardiovascular disease market.
- Analysts at The Globe and Mail have a "buy" rating on Amarin's stock, with a target price of around $25 per share. This represents a potential upside of around 20% from the current stock price.
Recent Financials:
- Amarin Corporation reported its Q4 2022 financial results in February, which showed a significant increase in revenue and profitability. The company's revenue increased by 24% year-over-year to $143.6 million, while its net income increased by 55% to $34.4 million.
- The company's cash and cash equivalents increased by 15% to $343.6 million, providing a strong foundation for future growth and investment.
Key Statistics:
- Market capitalization: $4.3 billion
- Current stock price: around $20.50 per share
- 52-week range: $14.50 - $23.50 per share
- Dividend yield: 0.00%
I hope this summary provides you with a good overview of Amarin Corporation (AMRN) stock from The Globe and Mail. If you have any specific questions or would like more information, feel free to ask!